NCT06992713招募中1 期
A Phase Ia, First-in-human, Clinical Study of the Safety, Tolerability, and Pharmacokinetics of H1710 for Injection in Participants With Advanced Solid Tumors
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 36
- 试验地点
- 6
- 主要终点
- Incidence and severity of treatment-emergent adverse events
研究概览
简要总结
This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.
详细描述
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of H1710 for Injection in participants with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults 18 years≤ age ≤ 75 years, irrespective of gender, ethnicity, financial, and educational background.
- •Signed Informed Consent Form (ICF) prior to screening.
- •Participants with histologically or cytologically confirmed advanced solid tumors, who have failed standard treatment, or have no standard treatment, or intolerant to or not suitable for standard treatment.
- •Participants must have measurable or evaluable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Predicted life expectancy of at least 3 months.
- •Adequate bone marrow reserve and organ function within 7 days prior to first dose of H1710.
排除标准
- •Presence of malignant tumor lesion(s) that is/are at high risk of bleeding as judged by the clinical study investigator.
- •Active clinically significant bleeding or conditions with a high risk of hemorrhage.
- •Major surgery or interventional therapy or significant trauma within 28 days prior to the first dose of H1710, or elective surgery during the clinical trial period.
- •Spinal or epidural anesthesia or loco-regional anesthesia within 24 hours prior to the first dose of H
- •Primary brain tumors. Active brain/meningeal metastases or central nervous system involvement who have clinical symptoms requiring medical intervention within 28 days prior to the first dose of H
- •Poorly controlled pleural effusion, pericardial effusion or ascites requiring repeated drainage as determined by investigators to be unsuitable for inclusion.
- •Any anti-tumor therapy within 28 days prior to first dose of H1710, except for those who can be included after judgment by investigators.
- •Participants have another active invasive malignancy, except for those who can be included after judgment by investigators.
- •Symptomatic congestive heart failure, unstable angina, sinus bradycardia, clinically uncontrollable hypertension, and ongoing cardiac arrhythmia.
- •Uncontrolled diabetes as determined by investigators.
- •History of clinically significant interstitial lung disease or pneumonia as determined by investigators.
- •Participants have a history of myocardial infarction within 6 months or coronary stenting within 12 months or a history of arterial thromboembolic event within 3 months before the first dose of H
- •Participants received a live attenuated vaccine within 28 days before the first dose of H1710 and/or plan to receive live vaccines during the study period unless approved by the clinical investigator and Sponsor.
- •Human immunodeficiency virus (HIV) infection or HIV positive, active Hepatitis B Virus (HBV) infection, active Hepatitis C Virus (HCV) infection. Except those who can be included after judgment by investigators.
- •Participants who have active bacterial, fungal or viral (except hepatitis virus) infections within 14 days before the first dose of H1710 and require intravenous or oral administration of antibiotics and/or other anti-infective therapeutic drugs.
- •Any adverse events due to prior anti-tumor therapy unresolved to ≤ Grade 1 of CTCAE 5.0 (except for toxicities judged by the clinical investigator to be of no safety risk, such as alopecia, other long term ≤ Grade 2 toxicities which would not impact the administration of H1710 and safety evaluation).
- •Participation in a clinical study of biological drug within 28 days, or within 14 days or 5 half-lives for small-molecule agents, before first dose of H1710, or current participation in other therapeutic investigational clinical trials.
- •Females who are pregnant or lactating or who intend to become pregnant during the clinical trial period and within 6 months after discontinuation of H1710 treatment. Female or Male who refuse using reliable birth control methods during the clinical trial period and within 6 months after discontinuation of H
- •Participants who have any clinically significant psychiatric, social, or medical condition that, as judged by the clinical investigator, could increase the subject's risk, interfere with protocol adherence, or affect the subject's ability to give informed consent are ineligible to participate in the study.
研究组 & 干预措施
H1710 for Injection
Experimental
Participants receive H1710 for Injection according to the protocol.
干预措施: H1710 for Injection (Drug)
结局指标
主要结局
Incidence and severity of treatment-emergent adverse events
时间窗: Up to ~ 18 months
Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0
Dose Limiting Toxicities（DLT）
时间窗: Up to ~ 18 months
Maximum Tolerated Dose (MTD)
时间窗: Up to ~ 18 months
Recommended Phase 2 Dose (RP2D)
时间窗: Up to ~ 18 months
次要结局
- Objective Response Rate (ORR)(Up to ~ 18 months)
- Disease Control Rate(DCR)(Up to ~ 18 months)
- Duration of Response (DOR)(Up to ~ 18 months])
- Progression Free Survival (PFS)(Up to ~ 18 months)
- Maximum Observed Concentration(Cmax) of H1710(Up to ~ 18 months)
- Time of Maximum Concentration (Tmax)of H1710(Up to ~ 18 months)
- Area Under the Concentration (AUC) of H1710(Up to ~ 18 months)
- Terminal Half life( t½) of H1710(Up to ~ 18 months)
- Clearance (CL) of H1710(Up to ~ 18 months)
研究者
研究点 (6)
Loading locations...
相似试验
Enrolling By Invitation
2 期
A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing CancersAdvanced Solid TumorsNCT05349409Suzhou Suncadia Biopharmaceuticals Co., Ltd.212
暂停
1 期
A Study of CS5001 in Patients With Advanced Solid Tumors and LymphomasAdvanced Solid TumorAdvanced LymphomaNCT05279300CStone Pharmaceuticals480
撤回
1 期
Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Characteristics of HHT120 in Healthy SubjectsHealthyNCT05414734Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
已完成
1 期
First-in-human Study of 10-1074-LS Alone and in Combination With 3BNC117-LSHuman Immunodeficiency VirusNCT03554408Rockefeller University77
招募中
1 期
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid TumorsNCT06960395Vir Biotechnology, Inc.450